[The influence of ezetimibe and simvaststin on platelet aggregation and protein c system in patients with coronary heart disease and hypercholesterolemia].
Therapy with ezetimib (10 mg daily for 2 weeks) caused a 24% reduction of plasma LDL cholesterol level (p < 0.05) and maximum ADP and collagen-induced platelet aggregation from 76.2 +/- 1.54 to 65.3 +/- 3.38% and from 71.5 +/- 3.98 to 53.6 +/- 5.24% (p < 0.05) respectively. Combination of ezetimibe and simvaststin did not produce an additional decrease in platelet aggregation.
V I
VI
Vashchenko
A I
AI
Kozobova
A E
AE
Filippov
A V
AV
Chechetkin
N N
NN
Popova
V N
VN
Vil'ianinov
T N
TN
Vashchenko
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001384:Azetidines / Q000627:therapeutic use*; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D011486:Protein C / Q000378:metabolism*; D019821:Simvastatin / Q000627:therapeutic use*
D000924:Anticholesteremic Agents; D001384:Azetidines; D011486:Protein C; D019821:Simvastatin; D000069438:Ezetimibe